Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma

International Journal of Cancer

Volumn 104, Issue 1, 2003, Pages 60-65

  Fricke, Elena ^a   Keller, Gisela ^a   Becker, Ingrid ^a   Rosivatz, Erika ^a   Schott, Christina ^a   Plaschke, Susanne ^a   Rudelius, Martina ^a   Hermannstädter, Christine ^a   Busch, Raymonde ^b   Höfler, Heinz ^a,c   Becker, Karl Friedrich ^a,c   Luber, Birgit ^a,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Aus dem Inst fur Tierpathologie   (Germany)

^d Inst Allg Pathol Pathologische A   (Germany)

Author keywords

Bcl 2; Diffuse type gastric carcinoma; E cadherin mutation; Ki 67; p53 accumulation; p53 mutation

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; UVOMORULIN;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL SURVIVAL; CONTROLLED STUDY; EXON; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN FAMILY; STOMACH CARCINOMA;

ADENOCARCINOMA; APOPTOSIS; CADHERINS; CELL ADHESION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; GENES, BCL-2; GENES, P53; HUMANS; KI-67 ANTIGEN; MUTATION; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037430149     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10879     Document Type: Article

References (50)

1. Kemler R. From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 1993;9:317-21.
2. Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol 2000;148:399-404.
3. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198:11-26.
4. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998;153:333-9.
5. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Höfler H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994;54:3845-52.
6. Becker KF, Kremmer E, Eulitz M, Becker I, Handschuh G, Schuhmacher C, Müller W, Gabbert HE, Ochiai A, Hirohashi S, Höfler H. Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody. Am J Pathol 1999;155:1803-9.
7. Muta H, Noguchi M, Kanai Y, Ochiai A, Nawata H, Hirohashi S. E-cadherin gene mutations in signet ring cell carcinoma of the stomach. Jpn J Cancer Res 1996;87:843-8.
8. Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki Y, Iwaya T, Terashima M, Saito K, Satodate R. Inactivation of the E-cadherin gene in primary gastric carcinomas and gastric carcinoma cell lines. Jpn J Cancer Res 1996;87:1153-9.
9. Berx G, Becker KF, Höfler H. van Roy F. Mutations of the human E-cadherin (CDH 1) gene. Hum Mutat 1998;12:226-37.
10. Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N, Berx G, Sobrinho-Simoes M. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 1999;79:459-65.
11. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type of carcinoma. Acta Pathol Microbiol Scand 1965;64:31-49.
12. Handschuh G, Candidus S, Luber B, Reich U, Schott C, Oswald S, Becke H, Hutzler P, Birchmeier W, Höfler H, Becker KF. Tumor-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 1999;18: 4301-12.
13. Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, Machado JC, Pinto E, Seruca R, Halling K, MacLeod P, Powell SM, Jackson CE, Ponder BA, Caldas C. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 1998;58:4086-9.
14. Guilford P. Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-5.
15. Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker KF, Mueller J, Siewert JR, Höfler H. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999;155: 337-42.
16. Richards FM, McKee SA, Rajpar MH, Cole TPR, Evans DGR, Jankowski JA, McKeown C, Sanders DSA, Maher ER. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999;8:607-10.
17. Prives C, Hall PA, The p53 pathway. J Pathol 1999;187:112-26.
18. Teh M, Lee YS. An immunohistochemical study of p53 protein in the different histological subtypes of gastric carcinoma. Pathology 1994; 26:432-4.
19. Lim BHG, Soong R, Grieu F, Robins PD, House AK, Iacopetta BJ. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 1996;69:200-4.
20. Brito MJ, Williams GT, Thompson H, Filipe MI. Expression of p53 in early (Tl) gastric carcinoma and precancerous adjacent mucosa. Gut 1994;35:1697-700.
21. Ranzani GN, Luinetti O, Padovan LS, Calistri D, Renault B, Burrel M, Amadori D, Fiocca R, Solcia E. p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev 1995;4:223-31.
22. Metcalfe A, Streuli C. Epithelial apoptosis. Bioessays 1997;19:711-20.
23. Kantak SS, Kramer R. E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 1998;273:16953-61.
24. Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, Day KC. E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem 1999;274:9656-64.
25. Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994;127:1375-80.
26. Peluso JJ. N-cadherin-mediated cell contact regulates ovarian surface epithelial cell survival. Biol Signals Recept 2000;9:115-21.
27. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
28. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ, Hanski C. Target genes of β-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999;96: 1603-8.
29. Luber B, Candidus S, Handschuh G, Mentele E, Hutzler P, Feller S, Voss J, Höfler H, Becker KF. Tumor-derived mutated E-cadherin influences beta-catenin localization and increases susceptibility to actin cytoskeletal changes induced by pervanadate. Cell Adhes Commun 2000;7:391-408.
30. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G. UICC International Union Against Cancer: TNM Atlas. Berlin, Heidelberg: Springer-Verlag, 1992.
31. Watanabe H, Jass JR, Sobin LH. World Health Organization: histological typing of oesophageal and gastric tumors. Berlin, Heidelberg: Springer-Verlag, 1990.
32. Becker KF, Kremmer E, Eulitz M, Schulz S, Mages J, Handschuh G, Wheelock MJ, Cleton-Jansen AM, Höfler H, Becker I. Functional allelic loss detected at the protein level in archival human tumors using allele-specific E-cadherin monoclonal antibodies. J Pathol 2002; 197:567-74.
33. Becker KF, Reich U, Schott C, Becker I, Berx G, van Roy F, Höfler H. Identification of eleven novel tumor-associated E-cadherin mutations. Hum Mutat 1998;13:171. Mutation in Brief no. 215.
34. Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Höfler H, Becker KF. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1 and twist in gastric cancer. Am J Pathol 2002;161:1881-91.
35. Oefner PJ, Underhill PA. DNA mutation detection using denaturing high-performance liquid chromatography (DHPLC). In: Dracopoli NC, Haines JL, Korff BR, Morton CC, Seidman CE, Seidman JG, Moir DT, Smith DR, eds. Current protocols in human genetics. New York: John Wiley and Sons, Inc., 1998. 7.10.1-7.10.12.
36. Keller G, Hartmann A, Mueller J, Hofler H. Denaturing high pressure liquid chromatography (DHPLC) for the analysis of somatic p53 mutations. Lab Invest 2001;81:1735-7.
37. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996;23:281-91.
38. Tahara E. Molecular aspects of invasion and metastasis of stomach cancer. Verh Dtsch Ges Pathol 2000;84:43-9.
39. Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S. p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 1993;54:759-64.
40. Strickler JG, Zheng J, Shu Q, Burgart LJ, Alberts SR, Shibata D. p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 1994;54:4750-5.
41. Liu XP, Tsushimi K, Tsushimi M, Oga A, Kawauchi S, Furuya T, Sasaki K. Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathol Int 2001;51:440-4.
42. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998;12:2973-83.
43. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997;91:325-34.
44. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell 1998;95:5-8.
45. Nigro JM, Aldape KD, Hess SM, Tlsty TD. Cellular adhesion regulates p53 protein levels in primary human keratinocytes. Cancer Res 1997;57:3635-9.
46. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997;38:773-6.
47. Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, MacDonald JS, Stemmermann G, Reed JC. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 1996;149:1449-57.
48. Sasaki CY, Lin H, Passaniti A. Expression of E-cadherin reduces bcl-2 expression and increases sensitivity to etoposide-induced apoptosis. Int J Cancer 2000;86:660-6.
49. Watabe M, Nagafuchi A, Tsukita S, Takeichi M. Induction of polarized cell-cell association and retardation of growth by activation of the E-cadherin-catenin adhesion system in a dispersed carcinoma line. J Cell Biol 1994;127:247-56.
50. St. Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 1998; 142:557-71.